A total of € 171.5 million was used for acquisitions and investments in other financial assets (2010: € 4,859.7 million). Of this amount, € 161.0 million (2010: € 4,843.7 million) was used for acquisitions. Investments in other financial assets totaled € 10.5 million (2010: € 16.0 million). The major acquisitions in fiscal 2011 were:
| XLS |
|
|
|
|
|
|
|
€ million |
Amnis |
Microbiology |
Other |
Total 2011 |
|
Purchase price paid |
77.3 |
70.8 |
15.0 |
163.1 |
|
Cash and cash equivalents acquired |
–0.7 |
–0.7 |
–0.7 |
–2.1 |
|
Acquisitions |
76.6 |
70.1 |
14.3 |
161.0 |
The divestment of Théramex in December 2010 led to in cash inflows of € 270.2 million in 2011, mainly as a result of the payment of our purchase price receivable. Cash inflows from the divestment of the Crop BioScience business amounted to € 200.9 million. The sale of Merck Capital Asset Management Limited, Malta, to Merck Pensionstreuhand e.V., Darmstadt, resulted in cash inflows of € 218.1 million.
Net cash outflows from changes in other financial assets amounting to € 1,057.7 million mainly results from short-term monetary deposits and the purchase of short-term securities and financial assets.